#USA #Washington, DC #Ascletis Pharma #ASC37 #ASC48

Ascletis Pharma to Present Groundbreaking Results at ObesityWeek® 2026

Ascletis Pharma Inc. has announced its intention to present significant findings regarding its innovative treatments for obesity at the upcoming ObesityWeek® 2026 conference, taking place from November 14 to 17 in Washington, DC, USA. The company is scheduled to feature two notable poster presentations focused on its oral small molecule GIPR agonist, ASC48, and a triple peptide agonist, ASC37, which targets GLP-1R, GIPR, and GCGR receptors.

Presentation Details

The first presentation will delve into the promising preclinical studies evaluating the ASC48 compound, which is positioned as a potential first-in-class therapy. Titled "Oral Small Molecule GIPR Agonist ASC48 for Obesity: In Vitro and In Vivo Studies," this session aims to share critical data that reflects the compound's efficacy in combating obesity by conducting extensive in vitro and in vivo experiments.

The second presentation revolves around the ASC37 compound, titled "ASC37 Showed 6-Fold Longer Half-Life Than Retatrutide in NHP and Marked Weight Loss in DIO Mice." This presentation highlights ASC37's favorable pharmacokinetic properties and its substantial impact on weight management, aiming to position it as a next-generation solution in obesity treatment strategies.

Company Insights

"We are excited to shed light on the latest preclinical progress from our robust and highly differentiated obesity portfolio, including both small molecules and peptides, at ObesityWeek® 2026," said Jinzi Jason Wu, Ph.D., Founder, Chairman, and CEO of Ascletis. This enthusiasm underscores the firm’s commitment to advancing therapeutic options tailored for obesity treatment, a growing public health challenge worldwide.

Ascletis Pharma Inc. is recognized as a fully integrated biotechnology entity dedicated to the development and commercialization of high-potential therapeutics aimed at metabolic diseases. With cutting-edge technologies such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and the Ultra-Long-Acting Platform (ULAP), Ascletis has been able to develop a variety of innovative drug candidates, demonstrating a unique approach in the pharmaceutical landscape.

Among its lead products are multiple oral small molecule candidates, including ASC30, designed for chronic weight management and diabetes, alongside various combinations that harness the synergistic potential of different receptors involved in metabolic regulation. Noteworthy is the ASC37 compound, aimed at providing an advanced treatment modality through subcutaneous administration and designed to deliver substantial weight loss effects over time.

The Path Forward

As Ascletis prepares for its presentations at ObesityWeek®, the company remains focused on its mission to address the complexities of obesity through innovative science and actionable therapeutic development. The upcoming findings presented during this pivotal conference could signify a substantial leap forward in obesity management, directly responding to the pressing global health crisis of obesity and related metabolic disorders.

The healthcare and biotechnology communities stand poised to witness firsthand the explorative and transformative research being spearheaded by Ascletis, further establishing the company's reputation as a forward-thinking leader in their field.

For additional details, please visit Ascletis' official website.

Conclusion

As more data emerges from Ascletis Pharma's research, the anticipation grows for potential breakthroughs that could redefine the treatment of obesity. The presentations at ObesityWeek® 2026 could pave the way for future advancements, not only enriching the therapeutic repertoire available but also improving patient outcomes in obesity management.